Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21934974 | 0.81 | KMT2A (0.50) | SMN1; SMN2HPGDKDM4EHSD17B10NPC1 | |
| SCHEMBL12859488 | 0.81 | BRAF (0.47) | BRAFPTGS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15715929 | 0.80 | SMN1; SMN2 (0.49) | PTGS1SMN1; SMN2PTGS2HPGDNPC1 | |
| SCHEMBL17291092 | 0.80 | ALDH1A1 (0.43) | BRAFPTGS1SMN1; SMN2PTGS2HPGD | |
| SCHEMBL12871680 | 0.80 | PTGS1 (0.46) | BRAFPTGS1SMN1; SMN2PTGS2HPGD | |
| SCHEMBL14747815 | 0.79 | PTGS2 (0.54) | PTGS1PTGS2NPC1RAB9ACYP1A2 | |
| SCHEMBL13602488 | 0.77 | SMN1; SMN2 (0.57) | BRAFSMN1; SMN2HPGDKDM4EHSD17B10 | |
| SCHEMBL9026152 | 0.77 | SMN1; SMN2 (0.49) | BRAFSMN1; SMN2HPGDKDM4EHSD17B10 | |
| SCHEMBL3381488 | 0.76 | BRAF (0.43) | BRAFPTGS1SMN1; SMN2PTGS2NPSR1 | |
| SCHEMBL20995055 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDKDM4ECYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-8455398-B2 | Amide compounds, preparation methods and uses thereof | SINOCHEM CORPORATION (CN) | 2013-06-04 | — | — | US | disclosed |
| US-7566683-B2 | Ethylene derivatives and pesticides containing said derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070049495-A1 | Ethylene derivatives and pesticides containing said derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049495-A1 | Ethylene derivatives and pesticides containing said derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049495-A1 | Ethylene derivatives and pesticides containing said derivatives | DDT, ECE1, EBPL | BRAF 2260/4885PTGS1 641/4885SMN1; SMN2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.